Syrup vs suspension
syrup vs suspension pharmaceutical dosage forms difference
https://laafon.com/what-is-the-difference-between-syrup-and-…
| Feature | Syrup | Suspension |
|---|---|---|
| Physical state | True solution (homogeneous) | Heterogeneous dispersion of insoluble solids in liquid |
| Drug solubility | Drug is dissolved in vehicle | Drug is insoluble; particles remain undissolved |
| Appearance | Clear (usually) | Cloudy, turbid |
| Label instruction | None required for mixing | "Shake well before use" |
| Syrup | Suspension | |
|---|---|---|
| Key excipients | Sucrose/polyols, preservatives, flavors, co-solvents | Wetting agents, suspending agents (e.g. xanthan gum, carboxymethylcellulose), flocculating agents, sweeteners, preservatives |
| Viscosity | Naturally high due to sugar | Adjusted using suspending agents to slow sedimentation |
| pH | Usually controlled for stability | Controlled; also affects particle charge (zeta potential) |
| Issue | Syrup | Suspension |
|---|---|---|
| Main risk | Crystallization of sugar ("graining"), microbial growth | Sedimentation, caking (hard sediment that cannot be redispersed), Ostwald ripening |
| Microbial risk | High sugar = osmotic protection but can still support mold | Needs preservatives; water activity matters |
| Freezing | May crystallize | May cause irreversible aggregation |
| Syrup | Suspension | |
|---|---|---|
| Shaking | Not needed | Always shake well before each dose |
| Storage | Avoid extreme temperatures (crystallization) | Avoid freezing; refrigerate if required |
| Shelf life after opening | Usually longer | Often shorter (especially reconstituted dry suspensions - typically 7-14 days) |
| Dosing device | Measuring spoon/cup | Oral syringe preferred for accuracy (particles affect volume) |
| Test | Syrup | Suspension |
|---|---|---|
| Clarity | Required (should be clear) | Not applicable |
| Particle size | Not applicable | Critical - affects sedimentation and dose |
| Redispersibility | Not applicable | Key quality test |
| Viscosity | Standard check | Important for pourability and shelf life |
| Assay | Content uniformity | Content uniformity after shaking |
When is an elixir or solution used instead of syrup or suspension?
elixir vs solution vs syrup pharmaceutical when to use indications differences
https://www.scribd.com/document/714068426/Differences-Betwee…
Is the drug SOLUBLE in water?
YES → Is sugar acceptable? → YES: Syrup | NO: Solution
NO → Is it soluble in alcohol? → YES: Elixir | NO: Suspension
| Feature | Syrup | Suspension | Elixir | Solution |
|---|---|---|---|---|
| Drug solubility | Water-soluble | Insoluble | Poorly water-soluble, alcohol-soluble | Water-soluble |
| Vehicle | Aqueous + high sugar | Aqueous + suspending agents | Hydroalcoholic (5-40% ethanol) | Aqueous (no/low sugar) |
| Homogeneous? | Yes | No (shake required) | Yes | Yes |
| Alcohol content | None/minimal | None | Yes (significant) | None |
| Palatability | High (sweet, viscous) | Moderate | Moderate (thinner than syrup) | Lower (may need flavoring) |
| Pediatric use | First choice | Common | Avoid (alcohol) | Good (sugar-free option) |
| Diabetic patients | Avoid (sucrose) | Check excipients | Avoid (alcohol) | Preferred |
| Absorption speed | Fast (dissolved) | Slower (must dissolve in GI tract) | Fast (dissolved) | Fast (dissolved) |
| Examples | Cough syrup, paracetamol syrup | Amoxicillin, antacid | Phenobarbital, digoxin | KCl, lactulose, IV fluids |
| Scenario | Best choice | Reason |
|---|---|---|
| Diabetic patient needs oral antibiotic | Solution or suspension | Avoid sucrose of syrup |
| Child needs antiepileptic, drug poorly soluble | Suspension or alcohol-free solution | Avoid alcohol of elixir |
| Drug insoluble in water AND alcohol | Suspension | Only option as a liquid |
| NG tube administration | Diluted solution | Avoids tube clogging |
| IV administration needed | Solution (sterile) | Only liquid form for parenteral use |
| Drug stable only in alcohol | Elixir | Alcohol acts as preservative/solvent |
| Long-term oral use in child | Sugar-free solution | Avoids dental caries from syrup |
Ceftriaxone injection order writing
ceftriaxone injection order writing dose route frequency reconstitution
https://medicalguidelines.msf.org/en/viewport/EssDr/english/…
https://globalrph.com/dilution/ceftriaxone-rocephin
Ceftriaxone [dose] [route] [frequency] x [duration]
Reconstitute with [diluent]; infuse over [time]
| Indication | Dose | Route | Frequency | Duration |
|---|---|---|---|---|
| Moderate-severe infections (general) | 1-2 g | IV/IM | Once daily (OD) | Per clinical response |
| Severe/life-threatening infections | 2 g | IV | OD or q12h | Per response |
| Bacterial meningitis | 2 g | IV | q12h | 7-14 days (organism-dependent) |
| Community-acquired pneumonia | 1-2 g | IV | OD | 5-7 days |
| Septicaemia/bacteraemia | 1-2 g | IV | OD | 10-14 days |
| Intra-abdominal infections | 1-2 g | IV | OD | 7-14 days (+ metronidazole) |
| UTI (pyelonephritis) | 1-2 g | IV | OD | 10-14 days |
| Uncomplicated gonorrhoea | 500 mg (or 1 g if >150 kg) | IM | Single dose | One-time |
| Surgical prophylaxis | 1 g | IV | Single dose 30-60 min pre-op | One-time |
| Lyme disease | 2 g | IV | OD | 14-28 days |
| Spontaneous bacterial peritonitis | 1-2 g | IV | OD | 5-7 days |
Maximum adult daily dose: 4 g/day
| Indication | Dose | Route | Frequency | Max daily |
|---|---|---|---|---|
| General serious infections | 50-75 mg/kg | IV/IM | OD or divided q12h | 2 g |
| Bacterial meningitis | 100 mg/kg | IV | OD or divided q12h | 4 g |
| Skin/soft tissue infections | 50-75 mg/kg | IV/IM | OD | 2 g |
| Acute otitis media | 50 mg/kg | IM | Single dose | 1 g |
| Gonorrhoea (child <45 kg) | 125 mg | IM | Single dose | - |
| Vial size | Diluent to add | Resulting concentration |
|---|---|---|
| 250 mg | 0.9 mL | ~250 mg/mL |
| 500 mg | 1.8 mL | ~250 mg/mL |
| 1 g | 3.6 mL | ~250 mg/mL |
| Vial size | Diluent to add (for ~100 mg/mL) | Further dilution for infusion |
|---|---|---|
| 250 mg | 2.4 mL | Dilute in 50 mL NS or D5W |
| 500 mg | 4.8 mL | Dilute in 50 mL NS or D5W |
| 1 g | 9.6 mL | Dilute in 100 mL NS or D5W |
| 2 g | 19.2 mL | Dilute in 100 mL NS or D5W |
| Incompatible with | Consequence |
|---|---|
| Calcium-containing solutions (Ringer's, Hartmann's, parenteral nutrition) | Fatal precipitate - never co-administer via any line |
| Vancomycin | Precipitate forms - flush line between doses |
| Aminoglycosides (gentamicin, amikacin) | Inactivation |
| Fluconazole | Precipitate forms |
| Amsacrine | Incompatible in admixture |
Always flush the IV line before and after ceftriaxone if any of the above were running.
| Population | Adjustment |
|---|---|
| Renal impairment alone | No dose adjustment needed up to 2 g/day |
| Hepatic impairment alone | No dose adjustment needed |
| Both renal + hepatic impairment | Monitor; do not exceed 2 g/day |
| Elderly | No adjustment needed up to 2 g/day |
| Neonates | Avoid if hyperbilirubinaemic; infuse over 60 min IV |
| Pregnancy | Category B - generally considered safe |
Ceftriaxone 1 g IV OD x 5-7 days
Reconstitute 1 g vial with 9.6 mL NS → dilute in 100 mL NS
Infuse over 30 minutes
Ceftriaxone 2 g IV q12h x 10-14 days
Reconstitute 2 g vial with 19.2 mL NS → dilute in 100 mL NS
Infuse over 30 minutes
Do NOT run with calcium-containing solutions
Ceftriaxone 500 mg IM STAT - single dose
Reconstitute with 1.8 mL 1% lidocaine
Deep IM injection into dorsogluteal muscle
Ceftriaxone 100 mg/kg/day IV = 2000 mg/day
Give as 1000 mg (1 g) IV q12h
Dilute in 100 mL NS, infuse over 30 min
Max 4 g/day
Why 19.2 ml or 9.6 ml? Why not round figures?
ceftriaxone reconstitution 9.6ml 19.2ml why 100mg/ml target concentration calculation
Volume of diluent = Dose (mg) ÷ Target concentration (mg/mL)
Diluent to add = (Dose ÷ Target concentration) − Powder volume
| Step | Calculation |
|---|---|
| Desired final volume at 100 mg/mL | 1000 mg ÷ 100 mg/mL = 10 mL |
| Powder displacement volume (~0.4 mL/g) | ~0.4 mL |
| Diluent to ADD | 10 - 0.4 = ~9.6 mL |
| Step | Calculation |
|---|---|
| Desired final volume at 100 mg/mL | 2000 mg ÷ 100 mg/mL = 20 mL |
| Powder displacement volume (~0.4 mL/g x 2 g) | ~0.8 mL |
| Diluent to ADD | 20 - 0.8 = ~19.2 mL |
| Vial | Diluent added | Powder vol | Final vol | Concentration |
|---|---|---|---|---|
| 250 mg | 2.4 mL | ~0.1 mL | ~2.5 mL | 100 mg/mL |
| 500 mg | 4.8 mL | ~0.2 mL | ~5.0 mL | 100 mg/mL |
| 1 g | 9.6 mL | ~0.4 mL | ~10 mL | 100 mg/mL |
| 2 g | 19.2 mL | ~0.8 mL | ~20 mL | 100 mg/mL |
1000 mg ÷ (10 mL + 0.4 mL powder volume) = ~96 mg/mL
Ceftriaxone 2 g IV q12h x 10-14 days Reconstitute 2 g vial with 19.2 mL NS → dilute in 100 mL NS Infuse over 30 minutes Hiw do i write it in prescription?
─────────────────────────────────────────────────────
MEDICATION ORDER
─────────────────────────────────────────────────────
Date: _____________
Time: _____________
Drug: Ceftriaxone sodium
Dose: 2 g
Route: Intravenous (IV) infusion
Frequency: Every 12 hours (q12h)
Duration: 10–14 days
Preparation: Reconstitute 2 g vial with 19.2 mL NS
(= 100 mg/mL), then dilute into 100 mL NS
Rate: Infuse over 30 minutes
Indication: Bacterial meningitis
Allergies: NKDA / [state known allergies]
Prescriber: _________________________ (signature)
Name (print): _____________
Reg. No.: _____________
Contact: _____________
─────────────────────────────────────────────────────
Inj. Ceftriaxone 2 g IV q12h × 14 days
Dilute in 100 mL NS — infuse over 30 min
(Reconstitute with 19.2 mL NS before dilution)
Inj. Ceftriaxone sodium 2 g
Route: I.V. (piggyback / IVPB)
Sig: 2 g IV q12h (infuse over 30 min in 100 mL NS)
Disp: 28 vials (2 g each) ← for 14 days at q12h = 28 doses
Refill: 0
| Element | What to Write |
|---|---|
| Drug name | Ceftriaxone sodium (generic preferred) |
| Dose | 2 g (not "2 grams" in shorthand - g is standard) |
| Route | IV infusion / IVPB (not just "IV" if infusion instructions differ from bolus) |
| Frequency | q12h OR "twice daily (BD/BID)" - both acceptable |
| Duration | × 10 days or × 14 days (specify clearly) |
| Diluent & volume | "in 100 mL NS" |
| Infusion rate/time | "over 30 minutes" |
| Reconstitution note | "Reconstitute with 19.2 mL NS" (pharmacy/nurse instruction) |
| Indication | Brief (e.g., meningitis) - good practice |
| Allergies | Always document |
| Prescriber signature | Mandatory |
| Date and time | Mandatory |
Reconstitute with 19.2 mL NS) is technically a nursing/pharmacy administration note, not a core prescribing element. In many hospitals it lives in the pharmacy label or nursing drug protocol rather than the prescription itself. However, for ward prescriptions or where a pharmacist is not preparing the dose, writing it explicitly prevents errors.Inj. Ceftriaxone 2 g IVPB in 100 mL NS — over 30 min — q12h × 14 days
Ivpb means
Primary IV line (e.g. NS or D5W running continuously)
|
|──── [IVPB bag: drug in 100 mL NS, hung higher]
| ↓ (flows first due to height)
└──── resumes primary line after IVPB is done
| Reason | Explanation |
|---|---|
| Safety | Some drugs (like ceftriaxone) are irritating or unsafe if pushed too fast - diluting in 100 mL and running over 30 min reduces vein irritation and side effects |
| Convenience | Drug infuses intermittently (q12h, q8h) without stopping the maintenance fluid |
| Compatibility | The primary line keeps the vein open between doses |
| Accuracy | Controlled infusion time ensures predictable drug delivery |
| Method | Volume | Time | Used When |
|---|---|---|---|
| IV Push (IVP / bolus) | Undiluted or small vol (5-20 mL) | Seconds to 5 min | Emergency drugs, furosemide, morphine |
| IVPB (piggyback) | 50-250 mL | 15-60 min | Intermittent antibiotics, most ward IV drugs |
| IV Infusion (continuous) | 250-1000 mL | Hours | Fluids, insulin, heparin, dopamine |
| IV Direct (slow push) | Undiluted | 3-5 min | Some specific drugs per protocol |
We don't have ivpb
Inj. Ceftriaxone 2 g IV q12h × 14 days
Reconstitute 2 g vial with 19.2 mL NS (= 100 mg/mL)
Add reconstituted solution into burette + top up with NS to 100 mL
Infuse over 30 minutes
Inj. Ceftriaxone 2 g IV q12h × 14 days
Reconstitute 2 g vial with 19.2 mL NS
Inject into 100 mL NS bottle and infuse over 30 minutes
Inj. Ceftriaxone 2 g IV q12h × 14 days
Reconstitute with 19.2 mL NS (100 mg/mL)
Give as slow IV injection over 2-4 minutes
Not preferred for meningitis dosing - use 100 mL dilution whenever possible.
| Setup Available | Best Method |
|---|---|
| Burette IV set | Option 1 - most controlled |
| 100 mL NS minibags/bottles available | Option 2 - simplest |
| Only large bags (500 mL) | Draw 100 mL NS into a syringe, add drug, give via syringe driver - or use burette |
| Nothing else available | Option 3 slow IV push |
Proper burette order
────────────────────────────────────────────────────────
INPATIENT MEDICATION ORDER
────────────────────────────────────────────────────────
Date: _______________
Time: _______________
Drug: Inj. Ceftriaxone sodium
Dose: 2 g
Route: IV (via burette)
Frequency: q12h (0800 hrs / 2000 hrs)
Duration: 14 days
Administration Instructions:
1. Reconstitute 2 g vial with 19.2 mL NS
2. Inject reconstituted solution into burette
3. Top up burette with NS to make 100 mL total
4. Run over 30 minutes
5. Flush IV line with 10 mL NS after completion
Indication: Bacterial meningitis
Allergies: _______________
Prescriber signature: _____________________
Name (print): _____________________
Reg. No.: _____________________
Date/Time: _____________________
────────────────────────────────────────────────────────
Inj. Ceftriaxone 2 g IV (burette) q12h × 14 days
- Reconstitute with 19.2 mL NS → inject into burette
- Top up to 100 mL with NS
- Infuse over 30 min
- Flush with 10 mL NS post-infusion
| Step | Reason |
|---|---|
| Reconstitute with 19.2 mL NS | Achieves 100 mg/mL - fully dissolves powder |
| Inject into burette | Burette acts as the infusion chamber |
| Top up to 100 mL with NS | Final concentration = 20 mg/mL (within safe 10-40 mg/mL range) |
| Infuse over 30 min | Safe rate; reduces vein irritation |
| Flush 10 mL NS after | Clears drug remaining in tubing (dead space) - ensures full dose delivered |
Volume = 100 mL
Time = 30 minutes
Rate = 100 mL ÷ 30 min × 20 drops/mL
= 67 drops/minute
Rate = 100 ÷ 30 × 60 = 200 drops/minute
Microdrip is impractical here - use a macrodrip (20 drops/mL) set at ~67 drops/min for a 30-minute infusion.
Inj. Ceftriaxone 2 g IV (burette) q12h × 14 days
Reconstitute 2 g with 19.2 mL NS → burette → top up to 100 mL NS
Run at 67 drops/min (20 drops/mL set) over 30 min
Flush with 10 mL NS after
Ceftriaxone (250/2.5)
| Step | Calculation |
|---|---|
| Vial contains | 250 mg powder |
| Add diluent | 2.5 mL NS (or sterile water) |
| Powder displacement volume | ~0.1 mL |
| Final volume | ~2.6 mL |
| Concentration | ~250 mg ÷ 2.6 mL = ~96 mg/mL |
Technically not exactly 100 mg/mL (that requires 2.4 mL per the manufacturer), but 2.5 mL is used because it is a round, easy-to-draw figure and the difference is negligible clinically (~4%).
Reconstitute 250 mg vial with 2.5 mL NS
→ gives approximately 100 mg/mL solution
→ entire 2.5 mL = 250 mg dose
| Dose needed | Vial(s) | Reconstitution | Volume to draw |
|---|---|---|---|
| 250 mg | 1 × 250 mg vial | + 2.5 mL NS | Entire 2.5 mL |
| 500 mg | 2 × 250 mg vials | Each + 2.5 mL NS | 2.5 mL from each (or use 1 g vial) |
| 1 g | 1 × 1 g vial | + 10 mL NS | Entire 10 mL |
| 2 g | 1 × 2 g vial | + 20 mL NS | Entire 20 mL |
Notice the same logic: 1 g / 10 mL and 2 g / 20 mL are the ward-friendly round-number equivalents of the manufacturer's 9.6 mL and 19.2 mL.
Baby aging 5 month need ceftriaxone. Can't give fluid. How do i do dosing?
ceftriaxone IM dose 5 month infant fluid restriction pediatric mg/kg
| Indication | Dose | For 7 kg baby |
|---|---|---|
| General infection (sepsis, pneumonia) | 50 mg/kg/day OD | 50 × 7 = 350 mg OD |
| Severe sepsis | 50 mg/kg q12h | 50 × 7 = 350 mg q12h |
| Meningitis | 100 mg/kg/day (OD or divided q12h) | 100 × 7 = 700 mg/day → 350 mg q12h |
| Max daily dose (pediatric) | 2 g/day |
Use 250 mg vial:
- Add 0.9 mL NS or 1% lidocaine
- Gives 250 mg/mL concentration
- For 350 mg: use a 500 mg vial + 1.8 mL → draw 1.4 mL
| Vial | Reconstitution | Concentration | Volume for 350 mg |
|---|---|---|---|
| 500 mg vial | + 2 mL NS | 250 mg/mL | Draw 1.4 mL |
| 2 × 250 mg vials | Each + 1 mL NS | 250 mg/mL | Draw 1 mL from each = 1.4 mL total |
IM site in a 5-month-old: Anterolateral thigh (vastus lateralis) - standard IM site for infants. Do NOT use gluteal in infants under 1 year (underdeveloped muscle, sciatic nerve risk).
350 mg ÷ 100 mg/mL = 3.5 mL
→ Push 3.5 mL slowly over 3-5 min
→ Flush with 2 mL NS (minimal flush - just to clear the line)
Inj. Ceftriaxone 350 mg IM q12h × [duration]
Reconstitute 500 mg vial with 2 mL NS (250 mg/mL)
Draw 1.4 mL = 350 mg
Inject deep IM into right/left anterolateral thigh
Alternate sites each dose
Inj. Ceftriaxone 350 mg IV slow push q12h × [duration]
Reconstitute 500 mg vial with 5 mL NS (100 mg/mL)
Draw 3.5 mL = 350 mg
Give over 3-5 minutes
Flush with 2 mL NS after
| Point | Detail |
|---|---|
| Not a neonate | 5 months is past the neonatal period - ceftriaxone is safe (bilirubin displacement is a neonatal concern) |
| Lidocaine | Can use 1% lidocaine as diluent for IM to reduce pain - safe in infants (use 1%, NOT 2%) |
| Max single IM site volume | ~1 mL per site in infants - if >1 mL, split between two thighs |
| No calcium IV lines | Flush line well before and after - never co-administer with calcium |
| Duration | Depends on indication - typically 5-7 days for sepsis, 10-14 days for meningitis |
Baby: 5 months, ~7 kg, fluid restricted
Dose: Ceftriaxone 350 mg IM q12h
Reconstitute: 500 mg vial + 2 mL NS = 250 mg/mL
Draw: 1.4 mL per dose
Site: Anterolateral thigh (alternate each dose)
Volume given: 1.4 mL IM — zero IV fluid load
What are the signs of ceftriaxone adverse effects in infants?
ceftriaxone adverse effects signs infants clinical monitoring
Note: This is primarily a neonatal concern (under 4 weeks). Your 5-month-old is past this highest-risk window, but still monitor if jaundice appears.
Always keep adrenaline (epinephrine 0.01 mg/kg IM) ready when giving any antibiotic injection.
| Effect | Blood Test | Clinical Sign |
|---|---|---|
| Eosinophilia | ↑ eosinophils | Often none; may accompany rash |
| Thrombocytosis | ↑ platelets | Usually asymptomatic |
| Leukopenia | ↓ WBC | Increased susceptibility to infection |
| Haemolytic anaemia | ↓ Hb, positive Coombs | Pallor, jaundice, lethargy, tachycardia |
Using 1% lidocaine as diluent significantly reduces pain and local reaction.
This is preventable - never co-administer with calcium-containing fluids (including TPN).
| Timeframe | What to Check |
|---|---|
| During/immediately after injection | Rash, wheezing, pallor, limpness (anaphylaxis) |
| First 24-48 hours | Jaundice, rash, loose stools, injection site |
| Days 3-7 | Diarrhoea, biliary signs (irritability, vomiting, RUQ), urine output |
| Throughout course | Feeding, activity level, urine output, stool colour |
| If >7 days use | Consider USS abdomen for biliary sludge if abdominal symptoms appear |
| Sign | Likely Problem |
|---|---|
| Hives + wheeze + limpness | Anaphylaxis → Adrenaline IM NOW |
| Deep jaundice + lethargy | Hyperbilirubinaemia → stop, check bilirubin |
| Bloody diarrhoea | C. difficile colitis → stool culture, stop |
| No urine output + crying on urination | Nephrolithiasis → USS kidneys |
| RUQ pain + vomiting | Biliary pseudolithiasis → USS abdomen |
What are alternative antibiotics if infant develops ceftriaxone allergy?
alternative antibiotics ceftriaxone allergy infant pediatric cross reactivity cephalosporin
| Reaction Type | Examples | What It Means |
|---|---|---|
| Mild / non-severe | Rash, urticaria only | May still use other beta-lactams carefully |
| Severe / IgE-mediated | Anaphylaxis, angioedema, bronchospasm | Avoid all cephalosporins; caution with penicillins |
| Severe delayed (SCAR) | SJS, DRESS, TEN | Avoid ALL beta-lactams |
| Drug class | Cross-reactivity with ceftriaxone | Safety |
|---|---|---|
| Other cephalosporins | Low (~1-2%) if different side chain | Can often use (e.g. cefotaxime has same side chain - AVOID) |
| Penicillins | Very low (~1%) in reality | Usually safe, especially aminopenicillins |
| Carbapenems (meropenem) | Very low (<1%) | Generally safe |
| Aztreonam | Same side chain as ceftriaxone - AVOID | Cross-reacts significantly |
| Non-beta-lactams | None | Always safe to use |
Critical: Ceftriaxone and aztreonam share the same R1 side chain - a patient allergic to ceftriaxone has high risk of reacting to aztreonam too. This is a common exam and clinical trap.
| Alternative | Dose (5-month, ~7 kg) | Route | Notes |
|---|---|---|---|
| Ampicillin + Gentamicin | Ampicillin 50 mg/kg q6h + Gentamicin 7.5 mg/kg OD | IV/IM | First-line combo for infant sepsis; different class entirely |
| Meropenem | 20 mg/kg q8h (severe: 40 mg/kg q8h) | IV | Carbapenem; very low cross-reactivity; use for severe/resistant |
| Ampicillin-sulbactam | 50 mg/kg q6h | IV | Broader than ampicillin alone |
| Cefotaxime | AVOID | - | Same R1 side chain as ceftriaxone - cross-reacts |
| Alternative | Dose | Route | Notes |
|---|---|---|---|
| Meropenem | 40 mg/kg q8h | IV | Drug of choice for meningitis if cephalosporin allergy - excellent CSF penetration |
| Ampicillin + Gentamicin | Amp 75-100 mg/kg q6h + Gent 7.5 mg/kg OD | IV | Covers Listeria + GBS; gentamicin has poor CSF penetration - not ideal alone |
| Chloramphenicol | 25 mg/kg q6h | IV | Good CSF penetration; used in resource-limited settings; monitor for grey baby syndrome |
| Alternative | Dose | Route | Notes |
|---|---|---|---|
| Ampicillin | 50 mg/kg q6h | IV/IM | Covers Strep pneumoniae if sensitive |
| Meropenem | 20 mg/kg q8h | IV | Broad cover |
| Clindamycin | 10 mg/kg q8h | IV | If Staph suspected |
| Alternative | Dose | Route | Notes |
|---|---|---|---|
| Gentamicin | 7.5 mg/kg OD | IV/IM | Excellent gram-negative cover; monitor renal function |
| Amikacin | 15-22.5 mg/kg OD | IV/IM | If gentamicin resistant organisms |
| Meropenem | 20 mg/kg q8h | IV | For resistant organisms |
| Drug | Coverage | Infant Use |
|---|---|---|
| Gentamicin | Gram-negative aerobics | Safe; monitor drug levels + renal function |
| Amikacin | Gram-negatives incl. resistant | Safe; monitor levels |
| Vancomycin | Gram-positive (MRSA, Strep) | Safe in infants; monitor trough levels |
| Metronidazole | Anaerobes, C. diff | Safe; often used in combination |
| Chloramphenicol | Broad; good CNS penetration | Use with caution - grey baby syndrome risk; monitor levels |
| Clindamycin | Gram-positive, anaerobes | Safe in infants |
Ceftriaxone allergy in 5-month-old infant
|
┌─────────┴──────────┐
MILD rash ANAPHYLAXIS / SEVERE
| |
Can try meropenem Meropenem (safest)
or ampicillin + OR
gentamicin Gentamicin + Ampicillin
(completely different class)
|
DO NOT USE:
- Cefotaxime (same side chain)
- Aztreonam (same side chain)
- Any cephalosporin if severe reaction
| Rule | Detail |
|---|---|
| Never use aztreonam | Shares exact side chain with ceftriaxone |
| Never use cefotaxime | Same R1 side chain - high cross-reactivity |
| Meropenem is the safest beta-lactam alternative | <1% cross-reactivity |
| Gentamicin + Ampicillin is completely different class | Zero cross-reactivity |
| For meningitis - meropenem is the go-to | Best CSF penetration among alternatives |
| Always document the allergy clearly | Type of reaction + date + drug |
Linezolid dosing
linezolid dosing adults pediatric infants IV oral indications
https://idmp.ucsf.edu/content/linezolid
| Indication | Dose | Route | Frequency | Duration |
|---|---|---|---|---|
| All serious infections (standard) | 600 mg | IV or PO | q12h | Per indication |
| Nosocomial / CAP pneumonia | 600 mg | IV/PO | q12h | 10-14 days |
| Complicated skin & soft tissue | 600 mg | IV/PO | q12h | 10-14 days |
| VRE infections | 600 mg | IV/PO | q12h | 14-28 days |
| MRSA bacteraemia / endocarditis | 600 mg | IV/PO | q12h | 14-42 days |
| Uncomplicated skin infections | 400 mg | PO only | q12h | 10-14 days |
| Mycobacterial infections (MDR-TB) | 600 mg | IV/PO | q24h (OD) | Months |
No renal dose adjustment required - linezolid is metabolised non-renally. No hepatic dose adjustment for mild-moderate impairment.
| Age group | Dose | Frequency | Max per dose |
|---|---|---|---|
| Preterm neonates (<34 weeks GA) | 10 mg/kg | q12h | - |
| Term neonates (0-4 weeks) | 10 mg/kg | q8-12h | - |
| Infants & children (1 month - 11 years) | 10 mg/kg | q8h | 600 mg |
| Children ≥12 years / adolescents | 600 mg (fixed) | q12h | 600 mg |
A 5-month-old at 7 kg: 10 mg/kg × 7 kg = 70 mg q8h
Inj. Linezolid 600 mg IV q12h × 14 days
Use ready-made 2 mg/mL bag (300 mL)
Infuse over 60 minutes
Do NOT add other drugs to linezolid bag
Inj. Linezolid 70 mg IV q8h × [duration]
Dilute from 2 mg/mL stock solution: draw 35 mL (= 70 mg)
Infuse over 30-60 minutes via burette
| Population | Adjustment |
|---|---|
| Renal impairment (CrCl >30) | No adjustment |
| Renal impairment (CrCl <30), course >10 days | Consider reducing to 300 mg q12h after 72h (reduces thrombocytopenia risk) |
| Haemodialysis | No adjustment (give after dialysis if on scheduled HD) |
| Hepatic impairment | No adjustment (mild-moderate) |
| Elderly | No adjustment |
| Pregnancy | Use only if benefit outweighs risk |
| Interacting Drug | Risk | Action |
|---|---|---|
| MAO inhibitors (phenelzine, tranylcypromine) | Serotonin syndrome / hypertensive crisis | Absolute contraindication |
| SSRIs / SNRIs (fluoxetine, sertraline, venlafaxine) | Serotonin syndrome | Avoid or use with extreme caution; wash-out period needed |
| Tramadol, pethidine | Serotonin syndrome | Avoid |
| Sympathomimetics (dopamine, adrenaline, pseudoephedrine) | Hypertensive crisis | Use lowest dose; monitor BP closely |
| Tyramine-rich foods (aged cheese, cured meats, red wine, fermented foods) | Hypertensive crisis | Counsel patient to avoid |
| Effect | Frequency | When | Monitor |
|---|---|---|---|
| Thrombocytopenia | Common with >2 weeks use | Progressive | FBC weekly if >2 weeks |
| Anaemia | Common | Progressive | FBC weekly |
| Peripheral neuropathy | Long-term use | After weeks-months | Symptoms: tingling, numbness |
| Optic neuropathy | Long-term use | After months | Visual acuity, colour vision |
| Lactic acidosis | Rare but serious | Any time | Lactate if unwell |
| Serotonin syndrome | With interacting drugs | Acute | Agitation, tremor, hyperthermia, tachycardia |
| Nausea, diarrhoea | Common | Early | Symptomatic |
| Point | Detail |
|---|---|
| Oral = IV | Switch freely - no dose change needed |
| No gram-negative cover | Never use alone for empirical sepsis unless gram-positive source confirmed |
| Reserve for resistant organisms | MRSA, VRE, MDR-TB - do not use for routine infections |
| FBC monitoring | Check weekly if treatment >2 weeks |
| Duration limit | Try to keep <28 days to minimise toxicity |
| Stewardship | Many hospitals require ID approval for linezolid |
Anj. Linezolid (600/300) 35 ml iv tds @ 17.5 drops/min Is it ok?
10 mg/kg × 7 kg = 70 mg per dose ✓
q8h (TDS) for infant <12 years ✓
70 mg × 3 = 210 mg/day ✓
Rate formula:
drops/min = Volume (mL) × drop factor (drops/mL) ÷ Time (min)
17.5 = 35 × 20 ÷ Time
Time = 35 × 20 ÷ 17.5
Time = 700 ÷ 17.5
Time = 40 minutes
| Parameter | Written Order | Correct? |
|---|---|---|
| Concentration | 2 mg/mL (600 mg/300 mL) | ✓ |
| Dose per administration | 35 mL = 70 mg | ✓ (10 mg/kg for 7 kg) |
| Frequency | TDS (q8h) | ✓ (infant <12 yrs) |
| Daily dose | 210 mg/day | ✓ |
| Drip rate | 17.5 drops/min | ✓ |
| Infusion time | 40 minutes | ✓ (within 30-120 min) |
Time = 35 × 20 ÷ 18 = 38.9 min ≈ 39 minutes